Template:Pyelonephritis antibiotics: Difference between revisions

No edit summary
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
''Treatment is targeted at [[E. coli]], [[Enterococcus]], [[Klebsiella]], [[Proteus mirabilis]], [[S. saprophyticus]]''
''Treatment is targeted at [[E. coli]], [[Enterococcus]], [[Klebsiella]], [[Proteus mirabilis]], [[S. saprophyticus]].''
====Outpatient====
====Outpatient====
''Consider one dose of [[Ceftriaxone]] 1g IV or [[Gentamycin]] 7mg/kg IV if the regional susceptibility of [[TMP/SMX]] or [[Fluoroquinolones]] is <80%''
''Consider one dose of [[Ceftriaxone]] 1g IV or [[Gentamycin]] 7mg/kg IV if the regional susceptibility of [[TMP/SMX]] or [[Fluoroquinolones]] is <80%''
Line 12: Line 12:
====Adult Inpatient Options====
====Adult Inpatient Options====
*[[Ciprofloxacin]] 400mg IV q12hr '''OR'''
*[[Ciprofloxacin]] 400mg IV q12hr '''OR'''
*[[Ceftriaxone]] 1gm IV QD '''OR'''
*[[Ceftriaxone]] 1gm IV QD <span style="color:red">'''(Preferred in pregnancy)'''</span> '''OR'''
*Cefotaxime 1-2gm IV q8hr '''OR'''
*Cefotaxime 1-2gm IV q8hr '''OR'''
*[[Gentamicin]] 3mg/kg/day divided q8hr +/- [[ampicillin]] 1–2 gm q4hr '''OR'''
*[[Gentamicin]] 3mg/kg/day divided q8hr +/- [[ampicillin]] 1–2 gm q4hr '''OR'''

Latest revision as of 22:37, 21 September 2022

Treatment is targeted at E. coli, Enterococcus, Klebsiella, Proteus mirabilis, S. saprophyticus.

Outpatient

Consider one dose of Ceftriaxone 1g IV or Gentamycin 7mg/kg IV if the regional susceptibility of TMP/SMX or Fluoroquinolones is <80%

Adult Inpatient Options

Pediatric Inpatient Options

  1. Gupta K, Hooton TM, Naber KG, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women. Clinical Infectious Diseases. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257
  2. Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011 Oct 1;84(7):771-6.
  3. Acute Pyelonephritis in Adults. Johnson, JR and Russo, TA. New England Journal of Medicine 2018; 378:48-59.
  4. Sandberg T. et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012 Aug 4;380(9840):484-90.